
Pfizer Inc. announced Tuesday that it has launched a trial that will compare its existing COVID-19 vaccine against a new version tailored to beat back the highly contagious Omicron variant. “While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we… read on > read on >